Rodman & Renshaw initiated coverage on Mannkind with a new price target
$MNKD
Biotechnology: Pharmaceutical Preparations
Health Care
Rodman & Renshaw initiated coverage of Mannkind with a rating of Buy and set a new price target of $8.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $12.00 | Outperform | Mizuho |
| 2/10/2025 | $11.00 | Outperform | Wedbush |
| 12/20/2024 | $9.00 | Overweight | Wells Fargo |
| 12/19/2024 | $7.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 9/9/2024 | $7.00 → $8.00 | Outperform | Leerink Partners |
| 6/13/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/10/2023 | $10.00 | Outperform | Wedbush |
| 2/28/2022 | $6.50 → $6.00 | Buy | HC Wainwright & Co. |